Thrombotic microangiopathy complicating bortezomib-based therapy for multiple myeloma

Leukemia and Lymphoma

Volumn 56, Issue 7, 2015, Pages 2185-2186

  Chan, Kah Lok ^a   Filshie, Robin ^a   Nandurkar, Harshal ^a   Quach, Hang ^a  

^a ST VINCENT S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CREATININE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; ENOXAPARIN; HAPTOGLOBIN; HEMOGLOBIN; LACTATE DEHYDROGENASE; LENALIDOMIDE; PARAPROTEIN; TECHNETIUM 99M; THALIDOMIDE; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ABDOMINAL PAIN; ACUTE KIDNEY FAILURE; ADULT; CANCER PATIENT; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; CONFUSION; CONTINUOUS HEMOFILTRATION; CREATININE BLOOD LEVEL; DIARRHEA; FEMALE; HEMODIALYSIS; HEMOGLOBIN BLOOD LEVEL; HOSPITAL ADMISSION; HUMAN; KIDNEY FAILURE; LACTATE DEHYDROGENASE BLOOD LEVEL; LETTER; LUNG EDEMA; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; PARAPROTEINEMIA; PEPTOCLOSTRIDIUM DIFFICILE; PLASMAPHERESIS; PRIORITY JOURNAL; PROCTOCOLITIS; RECTUM HEMORRHAGE; REMISSION; RENAL REPLACEMENT THERAPY; SUPERIOR MESENTERIC VEIN; THROMBOCYTE COUNT; THROMBOTIC THROMBOCYTOPENIC PURPURA; TRANSVERSE COLON; URINE VOLUME; VERNER MORRISON SYNDROME; VIRAL GASTROENTERITIS; CANCER STAGING; CHEMICALLY INDUCED; COMPLICATION; PROGNOSIS; THROMBOTIC MICROANGIOPATHIES;

BORTEZOMIB; FEMALE; HUMANS; MIDDLE AGED; MULTIPLE MYELOMA; NEOPLASM STAGING; PROGNOSIS; REMISSION INDUCTION; THROMBOTIC MICROANGIOPATHIES;

EID: 84938124821     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2014.977887     Document Type: Letter

References (10)

1. BellWR,BraineHG,NessPM, et al. Improvedsurvivalinthrombotic thrombocytopenic purpura-hemolytic uremic syndrome-clinical experience in 108 patients. N Engl J Med 1991;325:398-403.
2. Ruggenenti P, Noris M, Remuzzi G. Thrombotic microangiopathy, hemolytic uremic syndrome, and thrombotic thrombocytopenic purpura. Kidney Int 2001;60:831-846.
3. Shortt J, Oh DH, Opat SS. ADAMTS13 antibody depletion by bortezomib in thrombotic thrombocytopenic purpura. N Engl J Med 2013;368:90-92.
4. Boccadoro, Morgan G, Cavenagh J. Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy. Cancer Cell Int 2005;5:18.
5. Eremina V, Jefferson JA, Kowalewska J, et al. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med 2008;358:1129-1136.
6. Morita R, Hashino S, Shirai S, et al. Thrombotic microangiopathy after treatment with bortezomib and dexamethasone in a patient with multiple myeloma. Int J Hematol 2008;88:248-250.
7. Moore H, Romeril K. Multiple myeloma presenting with a fever of unknown origin and development of thrombotic thrombocytopenic purpura post-bortezomib. Intern Med J 2011;41:348-350.
8. Salmenniemi U, Remes K. Thrombotic microangiopathy associated with bortezomib treatment in a patient with relapsed multiple myeloma. Hematol Rep 2012;4:e13.
9. Mehta N, Saxena A, Niesvizky R. Bortezomib-induced thrombotic thrombocytopenic purpura. BMJ Case Rep 2012;2012:pii: bcr2012006461.
10. Blake-Haskins JA, Lechleider RJ, Kreitman RJ. Thrombotic microangiopathy with targeted cancer agents. Clin Cancer Res 2011;17:5858-5866.